Pembrolizumab-induced large duct cholangiopathy: Diagnosis and follow.up imaging.
J Postgrad Med
; 67(1): 43-45, 2021.
Article
in En
| MEDLINE
| ID: mdl-33533751
ABSTRACT
Immune-checkpoint inhibitor mediated hepatobiliary injury is an emerging concern in cancer treatment. Most of these adverse reactions are attributed to nivolumab and are characterized by panlobular hepatitis. Large duct cholangiopathy related to these drugs is extremely rare. We present a case of adenocarcinoma of lung treated with pembrolizumab who developed biochemical and imaging features consistent with cholangiopathy characterized by common bile duct dilatation, wall enhancement, and gallbladder wall edema. On follow-up in the fourth month, the imaging features persisted despite the normalization of liver enzymes. To the best of our knowledge, this is the first description of diagnosis and follow-up imaging of pembrolizumab-related cholangiopathy in imaging literature.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Digestive System Diseases
/
Chemical and Drug Induced Liver Injury, Chronic
/
Antibodies, Monoclonal, Humanized
/
Antineoplastic Agents, Immunological
Type of study:
Diagnostic_studies
Limits:
Humans
Language:
En
Journal:
J Postgrad Med
Year:
2021
Type:
Article
Affiliation country:
India